Compare Plug Power Inc (PLUG) vs Sanofi SA (SNY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Plug Power Inc vs Sanofi SA — how do they compare? Plug Power Inc trades at $2.19 (market cap $3.16B), while Sanofi SA trades at $43.12 (market cap $104.06B). The key difference: Sanofi SA is far larger — about 32.9× Plug Power Inc's market cap, and Sanofi SA pays a 5.61% dividend while Plug Power Inc pays none. Which is the better fit depends on your goals.
| PLUG | SNY | |
|---|---|---|
Market Cap | $3.16B | $104.06B |
Sector | Industrials | Health |
52-Week High | $4.14 | $52.34 |
52-Week Low | $1.44 | $41.33 |
Enterprise Value | $4.03B | $124.09B |
Dividend Yield | — | 5.61% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Plug Power (PLUG) trades at $2.26, up 4.15% today, but remains in a challenging fundamental position with persistent losses. The company shows modest revenue recovery to $710 million in 2025 but continues to report negative gross margins and substantial net losses. Technical indicators suggest a bullish short-term trend, while analyst sentiment remains divided with a $4.04 consensus price target representing significant upside potential from current levels.
While PLUG offers substantial upside based on analyst targets and growing electrolyzer demand, the investment carries high risk due to ongoing operational losses, negative cash flow, and heavy reliance on financing. The company's turnaround strategy shows early progress but requires sustained execution to achieve profitability amid competitive pressures in the hydrogen sector.
Sanofi (SNY) trades at $43.155, down 2.45% today, with a bearish technical signal from moving averages but bullish oscillators. The company reported strong Q2 2026 earnings, beating expectations with EPS of $1.21 versus $1.10 expected, and raised full-year guidance. Recent FDA approvals for COVID vaccines and EU approval for MenQuadfi in infants provide positive catalysts, though pipeline setbacks with an eczema drug withdrawal create uncertainty.
SNY presents a mixed outlook with solid fundamentals including a 5.4% dividend yield and reasonable valuation (P/E 22.94), but faces execution risks under new CEO leadership. Analyst consensus leans Hold (51.86%) with price target of $49.50, suggesting moderate upside potential. Key risks include drug pipeline challenges and competitive pressures in the pharmaceutical sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Plug Power Inc
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets—including material handling, e-mobility, power generation, and industrial applications.
Read more on PLUG →About Sanofi SA
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →
